Novel agents targeting immune checkpoints and costimulatory receptors, such as LAG‐3, OX40, HLA‐E, and 4‐1BB, are currently evaluated in clinical trials for HNSCC. The gene discussed is TNFRSF4; the disease is head and neck squamous cell carcinoma.